Reprint of: Recent Advances in Cytomegalovirus: An Update on Pharmacologic and Cellular Therapies

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 2, 2015, Pages S19-S24

  Boeckh, Michael ^a   Murphy, William J ^b   Peggs, Karl S ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiviral drugs; Cellular therapy; Cytomegalovirus; Natural killer cells

Indexed keywords

ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; CELL THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE SURVEILLANCE; GAMMA DELTA T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPESVIRIDAE; HUMAN; IMMUNOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS;

EID: 84921504241     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.12.034     Document Type: Review

References (57)

1. Pollack M., Heugel J., Xie H., et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011, 17:664-673.
2. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011, 2011:305-309.
3. Sellar R.S., Peggs K.S. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther 2012, 12:1161-1172.
4. Emery V., Zuckerman M., Jackson G., et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 2013, 162:25-39.
5. Sellar R.S., Peggs K.S. Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol 2012, 156:559-572.
6. Dropulic L.K., Cohen J.I. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther 2010, 88:610-619.
7. Marty F.M., Ljungman P., Papanicolaou G.A., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011, 11:284-292.
8. Marty F.M., Boeckh M. Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?. Curr Opin Virol 2011, 1:555-562.
9. Drew W.L., Miner R.C., Marousek G.I., Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. JClin Virol 2006, 37:124-127.
10. Lischka P., Hewlett G., Wunberg T., et al. Invitro and invivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010, 54:1290-1297.
11. Price N.B., Prichard M.N. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011, 1:548-554.
12. Kaul D.R., Stoelben S., Cober E., et al. First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 2011, 11:1079-1084.
13. Chemaly R.F., Ullmann A.J., Stoelben S., et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. NEngl J Med 2014, 370:1781-1789.
14. Marty F.M., Winston D.J., Rowley S.D., et al. CMX001 to prevent cytomegalovirusdisease in hematopoietic-cell transplantation. NEngl JMed 2013, 369:1227-1236.
15. Eid A.J., Razonable R.R. New developments in the management ofcytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965-981.
16. Avery R.K., Mossad S.B., Poggio E., et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010, 90:419-426.
17. Sellar R.S., Ward K.N., Thomson K.J., Peggs K.S. Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT. Bone Marrow Transplant 2012, 47:1482-1483.
18. Wolf D.G., Shimoni A., Resnick I.B., et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011, 90:183-186.
19. Shapira M.Y., Resnick I.B., Chou S., et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008, 46:1455-1457.
20. Reusser P., Riddell S.R., Meyers J.D., Greenberg P.D. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
21. Sellar R.S., Peggs K.S. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy 2012, 14:391-400.
22. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunityin immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257:238-241.
23. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
24. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99:3916-3922.
25. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
26. Peggs K.S., Verfuerth S., Pizzey A., et al. Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis 2009, 49:1851-1860.
27. Blyth E., Clancy L., Simms R., et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013, 121:3745-3758.
28. Feuchtinger T., Opherk K., Bethge W.A., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367.
29. Peggs K.S., Thomson K., Samuel E., et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis 2011, 52:49-57.
30. Schmitt A., Tonn T., Busch D.H., et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011, 51:591-599.
31. Uhlin M., Gertow J., Uzunel M., et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis 2012, 55:1064-1073.
32. Melenhorst J.J., Leen A.M., Bollard C.M., et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood 2010, 116:4700-4702.
33. Thomson K.J., Hart D.P., Banerjee L., et al. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 35:1065-1069.
34. Goodrich J.M., Bowden R.A., Fisher L., et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993, 118:173-178.
35. Leen A.M., Bollard C.M., Mendizabal A.M., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123.
36. Hanley P.J., Cruz C.R., Savoldo B., et al. Functionally active virus-specific Tcells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114:1958-1967.
37. Teschner D., Distler E., Wehler D., et al. Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis. Bone Marrow Transplant 2014, 49:138-144.
38. Cudkowicz G., Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. JExp Med 1971, 134:1513-1528.
39. Kiessling R., Klein E., Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975, 5:112-117.
40. Bennett M. Biology and genetics of hybrid resistance. Adv Immunol 1987, 41:333-445.
41. Kundig T.M., Schorle H., Bachmann M.F., et al. Immune responses in interleukin-2-deficient mice. Science 1993, 262:1059-1061.
42. Kennedy M.K., Glaccum M., Brown S.N., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. JExp Med 2000, 191:771-780.
43. Joncker N.T., Shifrin N., Delebecque F., Raulet D.H. Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment. JExp Med 2010, 207:2065-2072.
44. Barao I., Hanash A.M., Hallett W., et al. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory Tcells. Proc Natl Acad Sci U S A 2006, 103:5460-5465.
45. Ghiringhelli F., Menard C., Terme M., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-{beta}-dependent manner. JExp Med 2005, 202:1075-1085.
46. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: aunique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001, 97:3146-3151.
47. Barao I., Murphy W.J. The immunobiology of natural killer cells and bone marrow allograft rejection. Biol Blood Marrow Transplant 2003, 9:727-741.
48. Zamai L., Ahmad M., Bennett I.M., et al. Natural killer (NK cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. JExp Med 1998, 188:2375-2380.
49. Hallett W.H., Murphy W.J. Positive and negative regulation of natural killer cells: therapeutic implications. Semin Cancer Biol 2006, 16:367-382.
50. Waggoner S.N., Cornberg M., Selin L.K., Welsh R.M. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012, 481:394-398.
51. Alvarez M., Bouchlaka M.N., Sckisel G.D., et al. Increased antitumor effects using IL-2 with anti-TGF-beta reveals competition between mouse NK and CD8 T cells. JImmunol 2014, 193:1709-1716.
52. Andrews D.M., Estcourt M.J., Andoniou C.E., et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. JExp Med 2010, 207:1333-1343.
53. Lisnic V.J., Krmpotic A., Jonjic S. Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 2010, 13:530-539.
54. Dokun A.O., Kim S., Smith H.R., et al. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001, 2:951-956.
55. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. Nature 2009, 457:557-561.
56. Kim S., Poursine-Laurent J., Truscott S.M., et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005, 436:709-713.
57. Asai O., Longo D.L., Tian Z.G., et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. JClin Invest 1998, 101:1835-1842.